- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: h5G1.1 | h5G1.1VHC | Soliris®
eculizumab is an approved drug (FDA (2011), EMA (2007))
Compound class: Antibody
Comment: Eculizumab is a humanized monoclonal antibody targeting terminal complement activation, by binding to complement component C5 and inhibiting the production of C5a . It is the first approved therapy for paroxysmal nocturnal hemoglobinuria.
Eculizumab's developers, Alexion Pharmaceuticals have developed a next-generation version of eculizumab called ravulizumab (ALXN1210; FDA approved in December 2018), that has a longer circulating half-life than the originator, which allows for monthly dosing.
The evidence confirming C5, C5a and the C5a receptor as anti-inflammatory and anti-cancer drug targets is reviewed by Horiuchi and Tsukamoto (2016) .
Amgen's biosimilar ABP 959 (Bekemv®) was approved by the EMA in April 2023.
Samsung Bioepis' biosimilar (SB12; Epysqli®) was approved by the EMA in May 2023.
BOW080 (Polpharma Biologics, formerly Epirus Biopharmaceuticals) was in development, but this project appears to have been discontinued.
|Approved drug?||Yes (FDA (2011), EMA (2007))|
|International Nonproprietary Names|
|h5G1.1 | h5G1.1VHC | Soliris®|
|GtoPdb PubChem SID||178103466|
|Search PubMed clinical trials||eculizumab|
|Search PubMed titles||eculizumab|
|Search PubMed titles/abstracts||eculizumab|